|
May 7
|
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
|
|
May 6
|
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
|
|
Apr 24
|
Should You Hold Immunovant (IMVT)?
|
|
Apr 22
|
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
|
|
Apr 17
|
What Makes Immunovant (IMVT) a New Buy Stock
|
|
Mar 25
|
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
|
|
Mar 21
|
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
|
|
Mar 17
|
11 Oversold Biotech Stocks To Buy Right Now
|
|
Mar 14
|
10 Stocks George Soros and Insiders Are Crazy About
|
|
Mar 13
|
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
|
|
Mar 12
|
Immunovant Awarded U.S. Patent for IMVT-1402
|
|
Mar 8
|
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
|
|
Jan 22
|
Should You Invest in Immunovant (IMVT)?
|
|
Jan 19
|
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
|
|
Jan 13
|
Immunovant Inc CFO Eva Barnett Sells 3,515 Shares
|
|
Dec 26
|
Immunovant (IMVT) Rose on Positive Clinical Trial
|
|
Dec 21
|
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
|
|
Dec 21
|
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
|
|
Dec 21
|
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
|
|
Dec 20
|
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
|